



УДК 61

THE ROLE OF THE GUT MICROBIOME IN MODULATING NEURODEGENERATIVE DISEASES

Agayeva D.

Teacher,

Rozykulyyev B.

Student

The International University of Industrialists and Entrepreneurs

Ashgabat, Turkmenistan

Abstract. The intricate relationship between the gut microbiome and the central nervous system—known as the gut-brain axis—is gaining significant recognition in the pathogenesis of neurodegenerative disorders (NDs). This study investigates the mechanisms by which microbial communities in the gut influence the onset and progression of diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS). Key pathways explored include the production of microbial metabolites, particularly short-chain fatty acids (SCFAs) like butyrate, which affect blood-brain barrier integrity, neuroinflammation, and mitochondrial function.

Keywords: gut microbiome, neurodegenerative diseases, gut-brain axis, Alzheimer's disease (AD), Parkinson's disease (PD), short-chain fatty acids (SCFAs), neuroinflammation, dysbiosis, probiotics, therapeutic targets, diagnostic biomarkers.

The field of neuroscience has undergone a profound shift, moving beyond the central nervous system (CNS) to acknowledge the critical influence of peripheral systems, particularly the gastrointestinal tract. The gut microbiome, a vast and complex community of microorganisms, is now recognized as a key regulator of systemic health.

This dynamic ecosystem is integral to immune regulation, metabolic processes, and—most significantly—neurological function. Its ability to communicate with the brain through the gut-brain axis positions it at the nexus of health and neurological disease.

The gut-brain axis represents a sophisticated, bidirectional communication highway linking the gut and the CNS via neural (vagus nerve), endocrine (hormonal), and immunological pathways. It is the primary mechanism through which microbial activity influences cerebral function.

Disruptions to the balanced microbial community, a state referred to as dysbiosis, are increasingly implicated in the etiology and progression of chronic and debilitating neurodegenerative diseases (NDs). These diseases include Alzheimer's disease (AD) and Parkinson's disease (PD).



Alzheimer's disease, the leading cause of dementia, is pathologically defined by the accumulation of amyloid-beta plaques and hyperphosphorylated tau protein tangles. Emerging evidence suggests microbial metabolites contribute to systemic inflammation that exacerbates the neuroinflammatory response in the brain.

Parkinson's disease, characterized by the progressive loss of dopaminergic neurons, frequently presents with gastrointestinal symptoms, such as chronic constipation, often preceding motor symptoms by many years. This temporal relationship strongly suggests a potential peripheral, gut-based origin for the pathology.

The molecular connection is mediated by a multitude of signaling molecules synthesized by the gut microbiota. Among the most widely studied are short-chain fatty acids (SCFAs), which include butyrate, propionate, and acetate.

SCFAs are produced through the microbial fermentation of undigested dietary fibers and serve as crucial signaling molecules that modulate both the host's immune system and neurophysiological processes.

Butyrate, in particular, exhibits strong neuroprotective qualities by enhancing the integrity of the intestinal barrier and regulating the activity of microglia, the brain's resident immune cells.

Furthermore, the gut microbiome plays a role in the biosynthesis and regulation of key neurotransmitters, including serotonin and GABA (gamma-aminobutyric acid). Alterations in their synthesis can directly or indirectly impact cognitive function and mood, contributing to ND progression.

A crucial factor in ND pathogenesis is the link between gut dysbiosis and increased systemic and neuroinflammation. Dysbiosis can compromise the integrity of the intestinal mucosal barrier.

This compromised barrier allows bacterial products, such as lipopolysaccharides (LPS), to leak into the systemic circulation. This phenomenon, often called "leaky gut," triggers a chronic low-grade inflammatory response throughout the body.

Upon reaching the brain, these pro-inflammatory signals can activate glial cells (astrocytes and microglia), driving the sustained neuroinflammatory state that is characteristic of both AD and PD.

The current focus of research is shifting toward leveraging the microbiome for therapeutic intervention. Strategies such as the administration of probiotics and prebiotics aim to restore eubiosis and enhance beneficial metabolite production.

More radical approaches, such as Fecal Microbiota Transplantation (FMT), are being explored to fundamentally restructure the host's microbial community in hopes of slowing or reversing disease progression.



Identifying specific microbial signatures or metabolic profiles that correlate strongly with ND stages is essential for developing non-invasive diagnostic biomarkers. A simple gut-based test could offer earlier and more accurate diagnosis than current methods.

Targeting the gut microbiome offers a promising avenue for novel therapeutic development, shifting treatment paradigms from solely focusing on the brain to addressing peripheral drivers of pathology. Modifying the bacterial composition or augmenting the functionality of existing beneficial species could potentially mitigate the neurotoxic environment associated with protein misfolding.

The research also needs to address the variability in response to diet and interventions, which is highly dependent on the individual's unique microbial landscape. Personalized medicine approaches, informed by metagenomic sequencing, will be crucial for tailoring prebiotic or probiotic regimens to maximize their neuroprotective effects.

Beyond inflammation and metabolites, the microbiome can influence NDs through the regulation of mitochondrial function. Healthy bacteria contribute to mitochondrial stability and energy production in host cells, while dysbiosis can lead to oxidative stress and impaired neuronal energy metabolism—a hallmark of aging and neurodegeneration.

Furthermore, the influence of the gut microbiome extends to the clearance mechanisms of misfolded proteins. Studies suggest that a healthy gut environment can indirectly enhance the brain's ability to dispose of toxic aggregates, thereby limiting the spread of pathology from the periphery to the CNS.

Ultimately, integrating knowledge from microbiology, immunology, and neuroscience will be essential to translate these fascinating correlational findings into definitive causal relationships and, critically, into effective clinical treatments for patients suffering from neurodegenerative diseases.

In conclusion, understanding the intricate molecular and cellular crosstalk along the gut-brain axis is paramount. The microbiome is not merely an associated factor but a pivotal modulator of neurodegenerative risk and severity.

Reference:

1. Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, V., Bastiaanssen, T. F. S., Codagnone, M. N., ... & Dinan, T. G. (2019). The microbiota–gut–brain axis. *Physiological Reviews*, 99(4), 1877–2013.
2. Hao, F., & Lee, B. S. (2020). Gut Microbiota and Neurodegenerative Diseases: An Interplay with the Immune System. *Biomedicines*, 8(11), 470.
3. Sampson, T. R., Debelius, S. K., Thron, T., Phillips, S., Garfinkel, J., Sonnenburg, J. L., ... & Hsiao, E. Y. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. *Cell*, 167(6), 1492–1506.e12.



4. Zhuang, X., Gong, W., Lu, J., Zhang, C., Xiong, F., Sun, X., ... & Hu, M. (2020). The role of the gut microbiota in the pathogenesis of Alzheimer's disease. *Frontiers in Neuroscience*, 14, 1184.